The Efficacy and Tolerability of an Angiotensin II Receptor
Blocker, Telmisartan, in Thai Patients with Mild to Mode
rate Essential Hypertension
PEERA BURANAKITJAROEN, M.D., Ph.D.*, META PHOOJAROENCHANACHAI, M.D.*,
SURACHAI SARA VICH, Med.Tech.*, PANTIP SANGPRASERT, B.Sc., M.N.S.*
Affiliation : * Division of Hypertension, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok
10700, Thailand.
AbstractThis open-labeled single-blinded study was performed to evaluate the efficacy and tolerability
of telmisartan in the treatment of mild to moderate essential hypertension. Each patient was assigned
to take a placebo for 4 weeks followed by once daily-titrated telmisartan (40-80 mg) for 8 weeks.
"Office BP" and "24-hour ambulatory BP" measurements (24-h ABPM) were recorded as scheduled.
Thirty-one patients (10 males : 21 females) with a mean age of 48.1 years were enrolled. The final
SBP/DBP reductions of 14.6 ± 14.2/9.9 ± 6.2 mm Hg were obtained. Full response defined as office
DBP reduction of 2!:10 mm Hg from baseline and/or DBP <90 mm Hg was achieved in 73.3 per cent
of cases. Excluding 5 cases of white coat HT diagnosed by 24-h ABPM, full response rate (DBP
reduction of 2!:10 mm Hg from baseline and/or <85 mm Hg) was 76 per cent. Trough to peak ratio
and smoothness index for SBP/DBP were highly acceptable (0.75/0.76 and 0.97/1.01, respectively).
There were 4 cases of adverse events (2 cases of dizziness, 1 case of headache, and 1 case of acute
myocardial infarction).
Keywords : Hypertension, Treatment, Angiotensin Receptor Blocker
All Articles
Download
